Edition:
United Kingdom

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

8.27USD
20 Aug 2018
Change (% chg)

$-0.21 (-2.48%)
Prev Close
$8.48
Open
$8.56
Day's High
$8.65
Day's Low
$8.22
Volume
60,381
Avg. Vol
95,981
52-wk High
$14.62
52-wk Low
$4.89

Chart for

About

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR,... (more)

Overall

Beta: --
Market Cap(Mil.): $763.12
Shares Outstanding(Mil.): 93.52
Dividend: --
Yield (%): --

Financials

  ADAP.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.00 -- --
ROI: -32.06 1.78 14.61
ROE: -35.60 3.28 16.33

BRIEF-Adaptimmune Reports Q1 Loss Per Share $0.04

* ADAPTIMMUNE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE

09 May 2018

BRIEF-Adaptimmune Therapeutics Reports Quarterly Loss Per Ordinary Share Of $0.05

* ADAPTIMMUNE REPORTS FOURTH QUARTER / FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS UPDATE

15 Mar 2018

BRIEF-Adaptimmune Announces Responses In Second Solid Tumor Indication

* ADAPTIMMUNE ANNOUNCES RESPONSES IN SECOND SOLID TUMOR INDICATION WITH NY-ESO SPEAR T-CELLS

15 Mar 2018

Earnings vs. Estimates